Estrogen-TNF interactions and vascular inflammation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 6, 2007, Pages

  Ferreri, Nicholas R ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; F ACTIN; MEDROXYPROGESTERONE ACETATE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CAUSE OF DEATH; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG EFFICACY; EDITORIAL; ESTROGEN DEFICIENCY; HEART PROTECTION; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; INNATE IMMUNITY; ISCHEMIC HEART DISEASE; MACROPHAGE; MENOPAUSE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE; VASCULAR SMOOTH MUSCLE; VASCULITIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; CHEMOKINE CCL2; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; ESTROGENS; GENE EXPRESSION; HUMANS; INFLAMMATION; MYOCYTES, SMOOTH MUSCLE; NEUTROPHILS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447539952     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00193.2007     Document Type: Editorial

References (64)

1. Amrani Y, Ammit AJ, Panettieri RA Jr. Tumor necrosis factor receptor (TNFR) 1, but not TNFR2, mediates tumor necrosis factor-alpha-induced interleukin-6 and RANTES in human airway smooth muscle cells: role of p38 and p42/44 mitogen-activated protein kinases. Mol Pharmacol 60: 646-655, 2001.
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712, 2004.
3. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension 46: 76-81, 2005.
4. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Tumor necrosis factor-alpha and vascular angiotensin II in estrogen-deficient rats. Hypertension 48: 497-503, 2006.
5. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am J Pathol 137: 503-509, 1990.
6. Burry AF, Axelsen RA, Trolove P. Calcification in the renal medulla. A classification based on a prospective study of 2261 necropsies. Hum Pathol 7: 435-449, 1976.
7. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 98: 36-42, 1996.
8. Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, Adelman AG, Rabinovitch M. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 73: 534-539, 1995.
9. Drachman DE, Simon DI. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep 7: 44-49, 2005.
10. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37: 640-644, 2001.
11. Erickson SL, deSauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillet N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore MW. Decreased sensitivity to tumour-necrosis factor but normal T cell development in TNF-receptor-2-deficient mice. Nature 372: 560-563, 1994.
12. Faries PL, Marin ML, Veith FJ, Ramirez JA, Suggs WD, Parsons RE, Sanchez LA, Lyon RT. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J Vasc Surg 24: 463-471, 1996.
13. Frishman WH, Ismail AA. Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target? Cardiol Rev 10: 199-210, 2002.
14. Goetze S, Xi XP, Kawano Y, Kawano H, Fleck E, Hsueh WA, Law RE. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 33: 183-189, 1999.
15. Gourdy P, Mallat Z, Castano C, Garmy-Susini B, Mac Gregor JL, Tedgui A, Arnal JF, Bayard F. The atheroprotective effect of 17 beta-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. Atherosclerosis 166: 41-48, 2003.
16. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 49-57, 2002.
17. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8: 3-12, 2005.
18. Hernandez Schulman I, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol 26: 170-180, 2006.
19. Hoefer IE, van Royen N, Rectenwald JE, Bray EJ, Abouhamze Z, Moldawer LL, Voskuil M, Piek JJ, Buschmann IR, Ozaki CK. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation 105: 1639-1641, 2002.
20. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166: 357-365, 2006.
21. Javeshghani D, Sairam MR, Neves MF, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens 24: 1365-1373, 2006.
22. Jovinge S, Hultgardh Nilsson A, Regnstrom J, Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol 17: 490-497, 1997.
23. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Takeji T, Yasui T, Aono T. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol 184: 309-314, 2001.
24. Kappert K, Caglayan E, Huntgeburth M, Baumer AT, Sparwel J, Uebel M, Rosenkranz S. 17Beta-estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level. Am J Physiol Heart Circ Physiol 290: H538-H546, 2006.
25. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534, 2003.
26. McBane RD 2nd, Karnicki K, Miller RS, Owen WG. The impact of peripheral arterial disease on circulating platelets. Thromb Res 113: 137-145, 2004.
27. Miller AP, Feng W, Xing D, Weathington NM, Blalock JE, Chen YF, Oparil S. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 110: 1664-1669, 2004.
28. Miller VM, Jayachandran M, Heit JA, Owen WG. Estrogen therapy and thrombotic risk. Pharmacol Ther 111: 792-807, 2006.
29. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109: 672-693, 2004.
30. Murphy HS, Shayman JA, Till GO, Mahrougui M, Owens CB, Ryan US, Ward PA. Superoxide responses of endothelial cells to C5a and TNF-alpha: divergent signal transduction pathways. Am J Physiol Lung Cell Mol Physiol 263: L51-L59, 1992.
31. Nickenig G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S, Stablein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Bohm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97: 2197-2201, 1998.
32. Owonikoko TK, Fabucci ME, Brown PR, Nisar N, Hilton J, Mathews WB, Ravert HT, Rauseo P, Sandberg K, Dannals RF, Szabo Z. In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J Nucl Med 45: 94-100, 2004.
33. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087-1092, 2002.
34. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467, 1993.
35. Powledge TM. NIH terminates WHI oestrogen-only study. Lancet 363: 870, 2004.
36. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 346: 89-90, 1995.
37. Rayment NB, Moss E, Faulkner L, Brickell PM, Davies MJ, Woolf N, Katz DR. Synthesis of TNF alpha and TGF beta mRNA in the different micro-environments within atheromatous plaques. Cardiovasc Res 32: 1123-1130, 1996.
38. Reckelhoff JF. Cardiovascular disease, estrogen deficiency, and inflammatory cytokines. Hypertension 48: 372-373, 2006.
39. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 45: 170-174, 2005.
40. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 43: 918-923, 2004.
41. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102: 1697-1702, 2000.
42. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, Barrett-Connor E, Greendale GA. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 119: 167 e161-e168, 2006.
43. Rogers JL, Mitchell AR, Maric C, Sandberg K, Myers A, Mulroney SE. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 292: R794-R799, 2007.
44. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
45. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 89: 247-254, 1991.
46. Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 172: 1517-1520, 1990.
47. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 181: 607-617, 1995.
48. Sheng WS, Hu S, Ni HT, Rowen TN, Lokensgard JR, Peterson PK. TNF-alpha-induced chemokine production and apoptosis in human neural precursor cells. J Leukoc Biol 78: 1233-1241, 2005.
49. Siragy HM, Awad A, Abadir P, Webb R. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Endocrinology 144: 2229-2233, 2003.
50. Sites CK, Toth MJ, Cushman M, L'Hommedieu GD, Tchernof A, Tracy RP, Poehlman ET. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 77: 128-135, 2002.
51. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 104: 503-513, 1999.
52. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000.
53. Tanaka H, Sukhova G, Schwartz D, Libby P. Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 16: 12-18, 1996.
54. Tanaka H, Swanson SJ, Sukhova G, Schoen FJ, Libby P. Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-alpha and proliferate during acute rejection of rabbit cardiac allografts. Am J Pathol 147: 617-626, 1995.
55. Thorin-Trescases N, Bevan JA. High levels of myogenic tone antagonize the dilator response to flow of small rabbit cerebral arteries. Stroke 29: 1194-1200; discussion 1200-1191, 1998.
56. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452, 1992.
57. Waddell TK, Dart AM, Gatzka CD, Cameron JD, Kingwell BA. Women exhibit a greater age-related increase in proximal aortic stiffness than men. J Hypertens 19: 2205-2212, 2001.
58. Warner SJ, Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol 142: 100-109, 1989.
59. Wenger NK. Menopausal hormone therapy: currently no evidence for cardiac protection. Pediatr Blood Cancer 44: 625-629, 2005.
60. Wu Z, Maric C, Roesch DM, Zheng W, Verbalis JG, Sandberg K. Estrogen regulates adrenal angiotensin AT1 receptors by modulating AT1 receptor translation. Endocrinology 144: 3251-3261, 2003.
61. Xing D, Feng W, Miller AP, Weathington NM, Chen YF, Novak L, Blalock JE, Oparil S. Estrogen modulates TNF-α-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-β activation. Am J Physiol Heart Circ Physiol 292: H2607-H2612, 2007.
62. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 73: 205-209, 1993.
63. Young W, Mahboubi K, Haider A, Li I, Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-α- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 86: 906-914, 2000.
64. Zimmerman MA, Reznikov LL, Sorensen AC, Selzman CH. Relative contribution of the TNF-α receptors to murine intimal hyperplasia. Am J Physiol Regul Integr Comp Physiol 284: R1213-R1218, 2003.